NASDAQ:PRVB
Delisted
Provention Bio Inc. Stock News
$24.98
+0 (+0%)
At Close: Jul 24, 2023
The 5 Best- and Worst-Performing Mid-Cap Stocks in March 2023
10:58pm, Monday, 10'th Apr 2023
March was a good month for the stock market, with the S&P 500 gaining about 3.5%.
Why Provention Bio Stock Skyrocketed 256% This Week
04:56pm, Thursday, 16'th Mar 2023
Sanofi plans to acquire Provention Bio for around $2.9 billion. The deal will add Provention's type 1 diabetes drug Tzield to Sanofi's lineup.
Provention (PRVB) Skyrockets 260% on Buyout Offer From Sanofi
01:44pm, Tuesday, 14'th Mar 2023
Provention Bio (PRVB) to be acquired by pharma-giant Sanofi (SNY) for $2.9 billion. The transaction is likely to close by second-quarter 2023.
This biopharma stock jumped over 250% on Monday: what happened?
08:22pm, Monday, 13'th Mar 2023
Shares of Provention Bio Inc (NASDAQ: PRVB) more than tripled on Monday after Sanofi S.A. (EPA: SAN) confirmed plans of buying the biopharmaceutical company that focused on autoimmune diseases.
Monday Merger Mania Just Made These 2 Biotech Stocks Big Winners
07:15pm, Monday, 13'th Mar 2023
Markets were mixed on a volatile day on Wall Street. Sanofi offered to buy Provention Bio at a price more than triple where the stock closed Friday.
Regional banks pace decliners, as biotech deals lift Seagen and Provention Bio
11:17am, Monday, 13'th Mar 2023
Here are some of the biggest movers on Monday with banks firmly in focus after federal regulators stepped into protect deposits at fallen bank SVB.
Provention Bio shares soar after Sanofi agrees to buy company in $2.9B cash deal
10:15am, Monday, 13'th Mar 2023
French drugmaker Sanofi has announced an agreement to acquire US-based biopharmaceutical company Provention Bio Inc (NASDAQ:PRVB), which focuses on autoimmune diseases, for $25 per share in cash, or
Why Is Provention Bio (PRVB) Stock Up 263% Today?
08:13am, Monday, 13'th Mar 2023
Provention Bio (NASDAQ: PRVB ) stock is rocketing higher on Monday following news that Sanofi (NASDAQ: SNY ) is acquiring the company. That deal has Sanofi agreeing to acquire Provention Bio for $2
Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call
07:00am, Monday, 13'th Mar 2023
RED BANK, N.J. , March 13, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced it ha
Sanofi To Buy Provention Bio In $2.9 Billion Deal (SNY) (PRVB)
06:43am, Monday, 13'th Mar 2023
Sanofi (NASDAQ: SNY) announced it is buying Provention Bio (NASDAQ: PRVB) as part of a $2.9 billion deal. These are the details.
Sanofi to buy Provention Bio in deal worth $2.9 billion
02:49am, Monday, 13'th Mar 2023
French pharmaceutical group Sanofi said Monday that it will buy Provention Bio, Inc., a U.S.-based biopharmaceutical company focused on autoimmune diseases, for $25 per share in cash, in a deal with a
Provention Bio to Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
08:30am, Thursday, 23'rd Feb 2023
RED BANK, N.J. , Feb. 23, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today
2 Beaten-Down Stocks That Might Be too Cheap to Ignore
01:30pm, Wednesday, 22'nd Feb 2023 The Motley Fool
There is an argument for hitting the buy button, but it's important to consider the potential risks too.
Provention Bio: Good Prospects In Type 1 Diabetes, But Patent Protection Is A Worry
09:13am, Wednesday, 22'nd Feb 2023
PRVB got its teplizumab approved last year. The molecule is a wonderful new addition to T1D therapy; however, it has been in development for decades.
2 Beaten-Down Stocks That Might Be too Cheap to Ignore
08:30am, Wednesday, 22'nd Feb 2023
There is an argument for hitting the buy button, but it's important to consider the potential risks too.
